ArticleInfection and immunity2010
Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia.
Article in Infection and immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Metabolites of prostaglandin synthases as potential biomarkers of Lyme disease severity and symptom resolution.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Pooled it
- Potential role of extracellular vesicles in bacterial phagocytosis during Escherichia coli pneumonia in ex vivo perfused human lungs.Intensive care medicine experimental · 2026Article
- Leukotrienes in Innate Immunity: Still Underappreciated after All These Years?Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Extracellular vesicles in the treatment of oxidative stress injury: global research status and trends.Frontiers in molecular biosciences · 2023Article
- Toxoplasma gondii Infection Decreases Intestinal 5-Lipoxygenase Expression, while Exogenous LTBInfection and immunity · 2022Article
- Neutrophil Recruitment in Pneumococcal Pneumonia.Frontiers in cellular and infection microbiology · 2022Review
- sEH promotes macrophage phagocytosis and lung clearance of Streptococcus pneumoniae.The Journal of clinical investigation · 2021Article
- Article
- Toonaciliatin K attenuates the lung injury induced by lung infection of H1N1 influenza virus by regulating the NF-κB/MyD88/TLR-7 pathway in mice.Archives of medical science : AMS · 2020Article
- Review
- Mesenchymal Stem Cell-Derived Extracellular Vesicles Decrease Lung Injury in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Leukotriene BNature microbiology · 2019Article
- Macrophage-derived LTB4 promotes abscess formation and clearance of Staphylococcus aureus skin infection in mice.PLoS pathogens · 2018Article
- Ablation of the leptin receptor in myeloid cells impairs pulmonary clearance of Streptococcus pneumoniae and alveolar macrophage bactericidal function.American journal of physiology. Lung cellular and molecular physiology · 2018Article
- Too much of a good thing: How modulating LTBSeminars in immunology · 2017Review
- Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.Trends in pharmacological sciences · 2017Review
- Macrophage LTBJournal of lipid research · 2017Article
- Neutrophil derived LTB4 induces macrophage aggregation in response to encapsulated Streptococcus iniae infection.PloS one · 2017Article
- Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice.American journal of physiology. Lung cellular and molecular physiology · 2016Article
- Obesity: impact of infections and response to vaccines.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Leukotriene B(4) (LTB(4)) is a potent lipid mediator of inflammation formed by the 5-lipoxygenase (5-LO)-catalyzed oxidation of arachidonic acid. We have previously shown that (i) LTB(4) is generated during infection, (ii) its biosynthesis is essential for optimal antimicrobial host defense, (iii) LT deficiency is associated with clinical states of immunocompromise, and (iv) exogenous LTB(4) augments antimicrobial functions in phagocytes. Here, we sought to determine whether the administration of LTB(4) has therapeutic potential in a mouse model of pneumonia. Wild-type and 5-LO knockout mice were challenged with Streptococcus pneumoniae via the intranasal route, and bacterial burdens, leukocyte counts, and cytokine levels were determined. LTB(4) was administered via the intraperitoneal, intravenous, and intranasal routes prior to pneumococcal infection and by aerosol 24 h following infection. Leukocytes recovered from mice given S. pneumoniae and treated with aerosolized LTB(4) were evaluated for expression levels of the p47phox subunit of NADPH oxidase. Intrapulmonary but not systemic pretreatment with LTB(4) significantly reduced the lung S. pneumoniae burden in wild-type mice. Aerosolized LTB(4) was effective at improving lung bacterial clearance when administered postinoculation in animals with established infection and exhibited greater potency in 5-LO knockout animals, which also exhibited greater baseline susceptibility. Augmented bacterial clearance in response to LTB(4) was associated with enhanced monocyte recruitment and leukocyte expression of p47phox. The results of the current study in an animal model serve as a proof of concept for the potential utility of treatment with aerosolized LTB(4) as an immunostimulatory strategy in patients with bacterial pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.